4
Changes in Ownership
Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-23-053351
President & CEO sold 47,853 shares at $33.52 ($1,604,033)
- President & CEO acquired 47,853 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
KAKKIS EMIL D · President & CEO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-10-19 | Exercise or conversion : show line 1 in the form | +47,853 | $6.86 | $328,272 | 647,029 | D |
| 2023-10-19 | Sale : show line 2 in the form | −47,853 | $33.52 | $1,604,033 | 599,743 | D |
| Open-market sales · 47,853 sh · avg $33.52 · $1,604,033 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-10-19 | Exercise or conversion : show line 3 in the form Stock Option (Right to Buy) | −47,853 | 0 | D |
Loading xslF345X05/doc4.xml…